EYECARE: Ophthalmology Aurion Forms Medical Advisory Board With Eminent Ophthalmologists By Staff Friday, October 22, 2021 12:21 AM SEATTLE, BOSTON and TOKYO—Aurion Biotech, which is developing novel treatments for preventing blindness, has formed a medical advisory board composed of eminent ophthalmologists. The board will collaborate with the company’s executive team in clinical development, and is chaired by Edward Holland, MD, who was recently appointed as Aurion Biotech's chief medical advisor. “The doctors on this board are among the best in our field,” said Dr. Holland. “Their expertise, commitment to, and enthusiasm for Aurion Biotech’s cell therapy speak volumes about the transformational potential of this treatment to cure blindness resulting from corneal endothelial disease. I welcome their contributions. It’s a privilege to work closely with each of them.”In addition to Dr. Holland, the following physicians have been named to Aurion Biotech’s medical advisory board:John Berdahl, MD – Vance Thompson Vision – Sioux Falls, South DakotaEric Donnenfeld, MD – Ophthalmic Consultants of LI & CT – Fairfield, ConnecticutMarjan Farid, MD – Gavin Herbert Eye Institute, UC Irvine Health – Orange County, CaliforniaNicole Fram, MD – Stein Eye Institute, UCLA Geffen School of Medicine – Los Angeles, CaliforniaMatthew Giegengack, MD – Wake Forest University School of Medicine – Greensboro, North CarolinaJose Guell, MD – Instituto de Microcirurgía Ocular – Barcelona, SpainTerry Kim, MD – Duke University Eye Center – Durham, North CarolinaShigeru Kinoshita, MD and professor, Kyoto Prefecture University of Medicine – Kyoto, JapanRichard Lindstrom, MD – founder and attending surgeon, Minnesota Eye ConsultantsElizabeth Yeu, MD – Virginia Eye Consultants – Norfolk, VirginiaThe company’s first candidate in development is a cell therapy for the treatment of corneal endothelial dysfunction invented by Aurion Biotech medical advisory board member professor Kinoshita and his colleagues at Kyoto Prefecture University of Medicine in Japan.Aurion Biotech is currently preparing for an IND submission for clinical trials in the U.S.